Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

151 results about "Anti-Infective Agents" patented technology

Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.

Anti-infection augmentation foamable compositions and kit and uses thereof

Anti-infective foamable composition and kits include a foamable carrier; a therapeutically safe and effective concentration of an anti-infective agent; an augmenting agent selected from the group consisting of a keratolytic agent and a skin penetration enhancer; and a propellant. The composition is housed in a container and upon release is expandable to form a breakable foam. The foamable carrier is selected to generate a foam of good or excellent quality in the presence of the augmenting agent and anti-infective agent. Methods for treating, alleviating or preventing a disorder of the skin, a body cavity or mucosal surface, wherein the disorder involves a fungal, bacterial or viral infection as one of its etiological factors, is described.
Owner:FOAMIX PHARMACEUTICALS LIMITED

Anti-infective agents

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
Owner:ABBVIE INC

Antimicrobial protection for implantable medical device

InactiveUS20050267543A1Simple and effective and long lastingAvoid infectionAntibacterial agentsInternal electrodesAnti infectivesMedical device
An anti-infective covering for an implantable medical device is described. The covering may be a polymeric boot that comprises an anti-infective agent in an amount effective to prevent an infection when implanted in a pocket of a patient. The boot is configured to snuggly engage at least a portion of the implantable medical device. The boot may contain a side hole that allows a housing of the implantable medical device to serve as a return electrode. The boot may be placed about the implantable medical device to render the device anti-infective.
Owner:MEDTRONIC INC

Pharmaceutical delivery system

InactiveUS20050095245A1Reduce adverse effectsEffectively impact the life cycleAntibacterial agentsBiocideDiseaseGynecology
A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 μg to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng / mL versus hours) having an area under the curve (AUC) of less than about 600 ng / mL.hr.
Owner:DRAGTEK CORP

Homeopathic complex

InactiveUS20100316737A1Potency can be alteredSilicon organic compoundsBiocideCalcium in biologyDisease
The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and / or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, Lachesis muta or other remedy with a similar profile, Mercurius Solubilis or similar mercury containing remedy and Silica or other silica containing compounds.
Owner:FARRINGTON DANIEL +1

Compositions and methods for induction of th17 cells

Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.
Owner:THE UNIV OF TOKYO +2

Enhanced trans-keratin drug delivery

The teachings provided herein are directed to a system and method for delivering an anti-infective agent through the nail of a subject having a nail infection. The system can comprise a drug delivery mechanism comprising an anti-infective agent and a heating element and a holding mechanism for releasably attaching the drug delivery mechanism to the digit having the infected nail. The drug delivery mechanism does not comprise a nail-infection-agent-containing member or sponge for receiving and delivering the anti-infective agent to the infected nail. In addition, the holding mechanism comprises a substantially open structure that covers the infected nail and does not enclose the digit. The system facilitates an enhanced trans-keratin drug delivery of the anti-infective agent through the infected nail in a dark, warm, and moist environment that prevents the growth of fungi in the infected nail. The teachings also include a heatable bandage for treating an infected nail.
Owner:INNOVATION BIOMEDICAL DEVICES

Tissue Matrix System

The present application discloses matrix compositions to support the repair of tissue defects such as an injury to tendon tissue, ligament tissue, vascular tissue, dermal tissue, or muscle tissue. A matrix described herein comprises a polyester polymer entangled with a polysaccharide polymer. Also disclosed are methods of preparing a matrix, and methods of using a matrix in the repair of tissue. In certain configurations, a matrix can comprise a polyester cross-linked with a polysaccharide, which can be an oxidized polysaccharide. In some configurations, a matrix can further comprise one or more additional components, such as a growth factor or an anti-infective agent. In some configurations, a matrix can be a viscous fluid or a paste, while in other configurations a matrix can be comprised by a solid such as a plug, a granule or a membrane.
Owner:ISTO TECH II LLC

Novel liposomal formulations that form drug nanocrystals after freeze-thaw

Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
Owner:GRIFOLS

Anti-infective antimicrobial-containing biomaterials

InactiveUS20110038910A1Prevent and diminish chronic inflammationReduce infectionBiocideInorganic active ingredientsMedicineFatty acid
Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of loading them with silver compounds are described. The silver-containing biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.
Owner:ATRIUM MEDICAL

Anti-infection augmentation foamable compositions and kit and uses thereof

Anti-infective foamable composition and kits include a foamable carrier; a therapeutically safe and effective concentration of an anti-infective agent; an augmenting agent selected from the group consisting of a keratolytic agent and a skin penetration enhancer; and a propellant. The composition is housed in a container and upon release is expandable to form a breakable foam. The foamable carrier is selected to generate a foam of good or excellent quality in the presence of the augmenting agent and anti-infective agent. Methods for treating, alleviating or preventing a disorder of the skin, a body cavity or mucosal surface, wherein the disorder involves a fungal, bacterial or viral infection as one of its etiological factors, is described.
Owner:FOAMIX PHARMACEUTICALS LIMITED

Stable ophthalmic composition

InactiveUS20070148192A1Not cause any irritation/discomfort to the eyeMore acceptabilityAntibacterial agentsBiocideRoom temperatureTraditional medicine
The present invention provides a clear stable ophthalmic composition comprising (a) an anti-infective agent; (b) a steroidal anti-inflammatory agent; (c) a complexing agent capable of forming an inclusion complex and (d) other pharmaceutically acceptable excipients in a liquid vehicle such that the composition is free of any other complexation enhancing polymer and such composition when stored at room temperature for one year does not show any precipitation over the storage period.
Owner:SUN PHARMA INDS

Anti-infective agents

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
Owner:ABBVIE INC

Anti-infective agents useful against multidrug-resistant strains of bacteria

The invention relates to novel methods for using macrolide anti-infective agents. The macrolide anti-infective agents demonstrate antibacterial activity against multi-drug resistant strains of bacteria and, in particular, methicillin-resistant Staphylococcus aureus (MRSA). Methods for inhibiting the activity of multi-drug resistant bacterial organisms and methods for treating a bacterial infection caused by such organisms are described herein.
Owner:ABBVIE INC

Stable liquid formulations of Anti-infective agents and adjusted Anti-infective agent dosing regimens

Provided are methods of determining a resistance-adjusted dosage regimen of an anti-infective agent for treatment of an infection of a mammal by a resistant infective organism, wherein an effective dosage regimen of the anti-infective agent is known for treatment of an infection of the mammal by a susceptible strain of the infective organism. Methods of treating a cefepime resistant bacterial infection in a patient are also provided.
Owner:ELAN PHRMA INT LTD

Compacted hemostatic cellulosic aggregates

The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and / or into the wound of a patient.
Owner:CILAG GMBH INT

Substituted 1-benzazepines and derivatives thereof

This invention relates to substituted 1-benzazepines and derivatives thereof useful as anti-infective agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and to methods of using these compounds for killing bacteria and other microorganisms or inhibiting bacterial and other microorganism growth.
Owner:BIOPORT R&D

Artemisinin-based peroxide compounds as broad spectrum anti-infective agents

Described herein is the synthesis, bioassay results and utility of new C-9 and C-10 substituted artemisinin derivatives with easily functionalizable groups attached to the artemisinin skeleton through carbon chain or heteroatoms. Described also is the demonstration of this class of compounds for their broad-spectrum anti-parasitic activity. Certain of these analogs possess noticeable cytotoxicity deliberately focused on treatment of cancerous diseases.
Owner:MISSISSIPPI THE UNIV OF

Anti-infective agents

Compounds having the formulaare hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
Owner:ABBVIE INC

Sixteen-membered macrolide compounds

The present invention provides novel sixteen-membered macrolide compounds that are useful as anti-infective agents or as intermediates thereto. The present invention also provides methods for the preparation of these compounds, and methods and formulations for their use. In one aspect of the present invention, sixteen-membered macrolide possessing a side chain Z are provided where Z is aliphatic, aryl, alkylaryl, halide, .dbd.NOR.sup.3, .dbd.NNHR.sup.3, or --W--R.sup.3 where W is O, S, NC(.dbd.O)R.sup.4, NC(.dbd.O)OR.sup.4, NC(.dbd.O)NHR.sup.4 or NR.sup.4 where R.sup.3 and R.sup.4 are each independently hydrogen, aliphatic, aryl or alkylaryl. In another aspect of the present invention, bicyclic compounds are provided where one of the cyclic-components is a sixteen-membered macrolide and the other is a cyclic moiety whose cyclic structure is formed by between 3 and 10 atoms. In another aspect of the present invention, sixteen-membered macrolide compounds that bind to the domain II region of the 23S RNA are provided.
Owner:KOSAN BIOSCI

Hydroxylthienoquinolones and related compounds as anti-infective agents

Disclosed herein are hydroxylthienoquinolones and related compounds and their pharmaceutically acceptable salts useful as antiviral agents and having the general formulain which the variables R2, R6, and R7 are defined herein. Certain compounds provided herein possess potent antibacterial, antiprotozoal, or antifungal activity and are particularly efficacious for the treatment of MRSA infections. The invention also provides pharmaceutical compositions, pharmaceutical compositions containing a hydroxylthienoquinolone in combination with one or more other active agent, and methods of treating microbial infections in animals by administering an effective amount of a hydroxylthienoquinolone or related compound to an animal suffering from a microbial infection.
Owner:ACHILLION PHARMA INC

Isothiazoloquinolones and related compounds as anti-infective agents

The invention provides certain compounds and salts of Formula I and Formula II:which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula I and Formula II. The variables A1, R2, R3, R5, R6, R7, A8 and R9 are defined herein.
Owner:ACHILLION PHARMA INC

Use of herbal agents for potentiation of bioefficacy of anti infectives

The present invention relates to the use of bioenhancers to decrease the resistance of microbial strains to anti-infective such an antibiotics and antifungals by potentiating the activities of anti-infective. This may be usefuil to reduce resistance in bacteria and yeast to aid in the treatment of certain infections and disease and to lower the concentration of antiinfectives necessary to inhibit the growth of microbial strains.
Owner:COUNCIL OF SCI & IND RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products